Trial record 1 of 1 for:    remarqable
Previous Study | Return to List | Next Study

nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Biosense Webster, Inc.
Sponsor:
Information provided by (Responsible Party):
Biosense Webster, Inc.
ClinicalTrials.gov Identifier:
NCT01824394
First received: April 1, 2013
Last updated: July 16, 2014
Last verified: July 2014

April 1, 2013
July 16, 2014
March 2013
September 2015   (final data collection date for primary outcome measure)
  • Early-onset primary adverse events [ Time Frame: 7 Days ] [ Designated as safety issue: Yes ]
    Incidence of early-onset primary adverse events within 7 days of the atrial fibrillation ablation procedure.
  • Incidence of arrhythmia [ Time Frame: 3-12 Months ] [ Designated as safety issue: No ]
    Freedom from documented, symptomatic atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) episodes based on electrocardiographic data through the effectiveness evaluation period (3-12 months follow-up post ablation procedure) in the intention to treat (ITT) population as randomized.
  • Primary Safety Endpoint [ Time Frame: 7 Days ] [ Designated as safety issue: Yes ]
    Incidence of early-onset primary adverse events within 7 days of the atrial fibrillation ablation procedure.
  • Primary Effectiveness Endpoint [ Time Frame: 3-12 Months ] [ Designated as safety issue: No ]
    Freedom from documented, symptomatic atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) episodes based on electrocardiographic data through the effectiveness evaluation period (3-12 months follow-up post ablation procedure) in the intention to treat (ITT) population as randomized.
Complete list of historical versions of study NCT01824394 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation
reMARQable nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation

To demonstrate safety and effectiveness of nMARQ Catheter System [nMARQ] compared with THERMOCOOL® Navigational Family of catheters in treating subjects with drug-refractory symptomatic paroxysmal atrial fibrillation (PAF).

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Atrial Fibrillation
  • Device: nMARQ Navigation Catheters
  • Device: NaviStar ThermoCool Catheters
  • Experimental: nMARQ Catheter
    nMARQ Catheter System
    Intervention: Device: nMARQ Navigation Catheters
  • Active Comparator: NaviStar ThermoCool Catheters
    THERMOCOOL® Navigational family of catheters
    Intervention: Device: NaviStar ThermoCool Catheters
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
400
September 2018
September 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients with symptomatic paroxysmal AF who have had at least one AF episode documented within one (1) year prior to enrollment. Documentation may include ECG, transtelephonic monitor (TTM), Holter monitor (HM), or telemetry strip.
  2. Patients who have failed at least one antiarrhythmic drug (AAD; class I or III, or atrioventricular (AV) nodal blocking agents such as beta blockers and calcium channel blockers) as evidenced by recurrent symptomatic AF, or intolerance to the AAD.
  3. Age 18 years or older.
  4. Signed Patient Informed Consent Form (ICF).
  5. Able and willing to comply with all pre-, post-, and follow-up testing and requirements.

Exclusion Criteria:

  1. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
  2. Previous ablation for atrial fibrillation.
  3. Patients on amiodarone at any time during the past 3 months prior to enrollment.
  4. AF episodes lasting > 7 days.
  5. Any cardiac surgery within the past 60 days (2 months) or valvular cardiac surgical procedure (i.e., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve).
  6. Coronary artery bypass graft (CABG) procedure within the last 180 days (6 months).
  7. Awaiting cardiac transplantation or other cardiac surgery within the next 365 days (12 months).
  8. Documented left atrial thrombus on imaging.
  9. History of a documented thromboembolic event within the past one (1) year.
  10. Diagnosed atrial myxoma.
  11. Presence of implanted cardioverter defibrillator (ICD).
  12. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms.
  13. Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.
  14. Women who are pregnant (as evidenced by pregnancy test if subject is of child-bearing age and potential) or breast feeding.
  15. Acute illness or active systemic infection or sepsis.
  16. Unstable angina.
  17. Myocardial infarction within the previous 60 days (2 months).
  18. Left ventricular ejection fraction <40%.
  19. History of blood clotting or bleeding abnormalities.
  20. Contraindication to anticoagulation (i.e., heparin, dabigatran, Vitamin K Antagonists such as warfarin).
  21. Life expectancy less than 365 days (12 months).
  22. Enrollment in an investigational study evaluating another device or drug.
  23. Uncontrolled heart failure or NYHA Class III or IV heart failure.
  24. Presence of intramural thrombus, tumor or other abnormality that precludes catheter introduction or manipulation.
  25. Presence of a condition that precludes vascular access.
  26. Left atrial size >50 mm.
Both
18 Years and older
No
Contact: Josh Der (909) 839-8843
United States,   Czech Republic,   Italy
 
NCT01824394
reMARQable
No
Biosense Webster, Inc.
Biosense Webster, Inc.
Not Provided
Not Provided
Biosense Webster, Inc.
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP